On this episode of Stock Movers:
- French luxury group LVMH is on track for a seventh straight session of losses, the longest streak since March, after US President Donald Trump signaled he could impose a 200% tariff on French wines and champagne. 
- Ferretti’s second-largest investor is preparing to propose a shareholder vote to oust directors with connections to the yacht maker’s top owner, China’s Weichai Group, according to people familiar with the matter. 
- GSK agreed to buy Rapt Therapeutics, a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion.

On this episode of Stock Movers: - French luxury group LVMH is on track for a seventh straight session of losses, the longest streak since March, after US President Donald Trump signaled he could impose a 200% tariff on French wines and champagne. - Ferretti&rsquo;s second-largest investor is preparing to propose a shareholder vote to oust directors with connections to the yacht maker&rsquo;s top owner, China&rsquo;s Weichai Group, according to people familiar with the matter. - GSK agreed to buy Rapt Therapeutics, a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

LVMH Losses, Ferritti Plot, GSK Rapt

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/eac133f4-a0fa-455d-958e-b3d800a76294/transcript

On this episode of Stock Movers:
- GSK (GSK) agreed to buy Rapt Therapeutics (RAPT), a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion. The UK drug company will pay $58 a share, equivalent to an equity value of $2.2 billion, according to a statement Tuesday. The price represents a premium of 65% compared with Rapt Therapeutics’ closing price of $35.10 on Monday.
- 3M (MMM) expects profit and sales to expand this year, signaling the company’s push to prioritize higher-growth markets and accelerate the introduction of new products will continue to lift its results.Adjusted earnings will be $8.50 to $8.70 a share in 2026, the maker of Post-it notes, roofing granules and electronics materials said Tuesday in a statement that also revealed better-than-expected quarterly results. Analysts had expected $8.64 on average, according to the average of estimates compiled by Bloomberg. Adjusted sales will climb about 4%, the company said.
- Homebuilder D.R. Horton (DHI) missed analysts’ estimates for quarterly home orders even as mortgage rates slid. The company reported 18,300 signed contracts for the three months through December, up 3% from a year earlier, according to a statement Tuesday. Analysts were expecting 18,653, the average in a survey compiled by Bloomberg.

On this episode of Stock Movers: - GSK (GSK) agreed to buy Rapt Therapeutics (RAPT), a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion. The UK drug company will pay $58 a share, equivalent to an equity value of $2.2 billion, according to a statement Tuesday. The price represents a premium of 65% compared with Rapt Therapeutics&rsquo; closing price of $35.10 on Monday. - 3M (MMM) expects profit and sales to expand this year, signaling the company&rsquo;s push to prioritize higher-growth markets and accelerate the introduction of new products will continue to lift its results.Adjusted earnings will be $8.50 to $8.70 a share in 2026, the maker of Post-it notes, roofing granules and electronics materials said Tuesday in a statement that also revealed better-than-expected quarterly results. Analysts had expected $8.64 on average, according to the average of estimates compiled by Bloomberg. Adjusted sales will climb about 4%, the company said. - Homebuilder D.R. Horton (DHI) missed analysts&rsquo; estimates for quarterly home orders even as mortgage rates slid. The company reported 18,300 signed contracts for the three months through December, up 3% from a year earlier, according to a statement Tuesday. Analysts were expecting 18,653, the average in a survey compiled by Bloomberg.

Stock Movers: Rapt, 3M, D.R. Horton (Podcast)

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/49f15698-badd-4e4c-979b-b3d800c6179c/transcript

On this episode of Stock Movers:
- French luxury group LVMH is on track for a seventh straight session of losses, the longest streak since March, after US President Donald Trump signaled he could impose a 200% tariff on French wines and champagne. 
- Shares of Wise Plc jumped the most in more than seven months after the money-transfer firm gave an upbeat earnings guidance and said it’s on track to shift its primary listing to the US in the first half of this year.
- Italy’s Finance Ministry is backing Banca Monte dei Paschi di Siena SpA Chief Executive Officer Luigi Lovaglio for a new term in the role, according to people familiar with the matter.

On this episode of Stock Movers: - French luxury group LVMH is on track for a seventh straight session of losses, the longest streak since March, after US President Donald Trump signaled he could impose a 200% tariff on French wines and champagne. - Shares of Wise Plc jumped the most in more than seven months after the money-transfer firm gave an upbeat earnings guidance and said it&rsquo;s on track to shift its primary listing to the US in the first half of this year. - Italy&rsquo;s Finance Ministry is backing Banca Monte dei Paschi di Siena SpA Chief Executive Officer Luigi Lovaglio for a new term in the role, according to people familiar with the matter.

LVMH Down, Wise Listing, Monte dei Paschi Up

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/1477fc68-3af6-4491-a483-b3d8009baaf2/transcript

On this episode of Stock Movers:

- Bayer’s shares surged after the US Supreme Court said it would hear the company’s appeal in a Roundup case that could undercut thousands of lawsuits tied to the weedkiller.

- Workspace, a landlord that rents space on flexible terms to mostly small- and medium-sized London businesses, is shaking up its top management after a period of turbulence saw shares drop for two consecutive years.

- BMW and other european automakers plunged after US President Donald Trump threatened to hike tariffs again in the standoff over Greenland.

On this episode of Stock Movers: - Bayer&rsquo;s shares surged after the US Supreme Court said it would hear the company&rsquo;s appeal in a Roundup case that could undercut thousands of lawsuits tied to the weedkiller. - Workspace, a landlord that rents space on flexible terms to mostly small- and medium-sized London businesses, is shaking up its top management after a period of turbulence saw shares drop for two consecutive years. - BMW and other european automakers plunged after US President Donald Trump threatened to hike tariffs again in the standoff over Greenland.

WHSmith and Workspace's New Bosses, BMW Plunges

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/1dfa30f7-2c6b-43cc-beae-b3d700a74ffb/transcript

LVMH Losses, Ferritti Plot, GSK Rapt

In 1 playlist(s)

Stock Movers

Social links

Follow podcast

Recent clips